KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
KORU Medical Systems reported Q2 2026 revenue of $12.0 million, up 18.2% year-over-year, driven by volume gains in both domestic and international core markets. The company achieved profitability with net income of $0.25 million and positive adjusted EBITDA of $0.9 million, marking a significant operational inflection. Management executed a strategic pivot by withdrawing its 510(k) application for FreedomEDGE with Phesgo to focus on higher-volume molecules, while simultaneously acquiring a connected monitoring technology asset. A new multi-year supply agreement was also established to support long-term margin expansion.
Key figures
- Eps
- 0.01
- Revenue
- 12045420
- Guidance
- FY2026 revenue $47.5M-$48.5M; gross margin 62%-64%; positive adjusted EBITDA; year end cash >$7.5M
- Revenue Yoy
- 18.2%
- Cash
- 8287704
- Net income
- 252449
- Gross margin
- 65.1%
- Gross profit
- 7846208
- Adjusted ebitda
- 860383
- Pharma services revenue change
- -35.0%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.